Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GABRP | O00591 | 5/20 | 0.48 |
| ▸ | GABRD | O14764 | 5/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.48 |
| ▸ | GABRE | P78334 | 5/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 5/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31620610 | 0.86 | MAPK1 (0.59) | CYP1A2SMN1; SMN2RAB9AMAPK1NPC1 | |
| SCHEMBL10270980 | 0.86 | MAPK1 (0.59) | CYP1A2SMN1; SMN2RAB9AMAPK1NPC1 | |
| SCHEMBL749735 | 0.86 | CYP1A2 (0.45) | CYP1A2MAPTSMN1; SMN2HSP90AA1RAB9A | |
| SCHEMBL2140228 | 0.85 | NPC1 (0.50) | CYP1A2MAPTSMN1; SMN2RAB9AGABRP | |
| SCHEMBL712413 | 0.84 | CYP1A2 (0.50) | CYP1A2MAPTSMN1; SMN2HSP90AA1RAB9A | |
| SCHEMBL226698 | 0.84 | P4HTM (0.69) | HSP90AA1RAB9AGABRA1GABRG2GABRB3 | |
| SCHEMBL2891190 | 0.83 | GABRA1 (0.46) | CYP1A2MAPTSMN1; SMN2HSP90AA1RAB9A | |
| SCHEMBL15670153 | 0.82 | CYP1A2 (0.42) | CYP1A2MAPTSMN1; SMN2HSP90AA1RAB9A | |
| SCHEMBL82426 | 0.82 | CYP1A2 (0.55) | CYP1A2MAPTSMN1; SMN2RAB9AMAPK1 | |
| SCHEMBL31172628 | 0.82 | CYP1A2 (0.55) | CYP1A2MAPTSMN1; SMN2RAB9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403812-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2016-08-02 | — | — | US | disclosed |
| US-9403812-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2016-08-02 | — | — | US | disclosed |
| US-9403812-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2016-08-02 | — | — | US | disclosed |
| US-20150322057-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-11-12 | — | — | US | disclosed |
| US-20150322057-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-11-12 | — | — | US | disclosed |
| US-20150322057-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-11-12 | — | — | US | disclosed |
| US-9096587-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-08-04 | — | — | US | disclosed |
| US-9096587-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-08-04 | — | — | US | disclosed |
| US-9096587-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-08-04 | — | — | US | disclosed |
| US-20140031374-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO University Hospital, HF (NO) | 2014-01-30 | — | — | US | disclosed |
| US-20140031374-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO University Hospital, HF (NO) | 2014-01-30 | — | — | US | disclosed |
| US-20140031374-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO University Hospital, HF (NO) | 2014-01-30 | — | — | US | disclosed |
| EP-2649063-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | Oslo University Hospital HF (NO) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012076898-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076898-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322057-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | CTNNB1, WNT1, CTNNA1 | CYP1A2 1160/4885MAPT 2805/4885SMN1; SMN2 4693/4885 |
| US-20140031374-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | CTNNB1, WNT1, CTNNA1 | CYP1A2 1167/4885MAPT 2776/4885SMN1; SMN2 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.